A door has opened for MSD's launch of a subcutaneous version of cancer drug Keytruda in Germany. The Higher Regional Court Munich has lifted a preliminary injunction issued in the first instance. The decision marks a significant setback for US biotech Halozyme, which had secured the PI from the Regional Court Munich in late 2025.
20 November 2026 by Konstanze Richter
The dispute between Halozyme and Merck Sharp & Dohme and its European affiliates centres on Halozyme’s European patent EP 2 797 622. It protects a polypeptide variant underlying the subcutaneous formulation of pembrolizumab. MSD markets pembrolizumab as Keytruda, one of the world’s best-selling cancer drugs. In 2024, it generated approximately €25.8 billion in sales for the US pharmaceutical company.
San Diego-based company Halozyme Therapeutics develops oncological therapies targeting the tumour’s microenvironment. It alleged infringement of its MDAS patent EP 622 by Keytruda SC.
The Munich Regional Court had granted the PI in December 2025, prohibiting MSD from launching Keytruda SC in Germany. The subcutaneous formulation is injected under the skin rather than administered by infusion. It is intended to simplify treatment for patients. Halozyme licenses the underlying Enhanze and MDASE technologies that enable the subcutaneous administration of drugs.
Now, the Higher Regional Court Munich, under presiding judge Lars Meinhardt, overturned the first-instance decision and dismissed the PI application (case ID: 6 U 3726/25 e). This paves the way for MSD to launch its Keytruda SC in Germany.
In a press release published shortly after the ruling, Halozyme announced that it is now initiating main proceedings. In it, Mark Snyder, Chief Legal Officer of Halozyme states: “We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today’s decision”.
The German decision forms part of a broader multi-jurisdictional dispute over Keytruda SC. MSD has filed nullity actions against EP 622 in Germany, the Netherlands, France and the UK. Halozyme has pursued infringement claims in several of these jurisdictions.
In a ruling handed down in early October, the District Court of The Hague upheld Halozyme’s European patent. It also issued a cross-border injunction covering eight countries, prohibiting MSD from marketing Keytruda.
Parallel litigation is also ongoing in the UK. The High Court recently rejected MSD’s application for expanded disclosure of Halozyme’s experimental documents. In the US, Halozyme is pursuing litigation against MSD before the federal district court in New Jersey. It alleges that Qlex, the subcutaneous formulation marketed there, infringes 15 patents relating to its MDAS technology.
Halozyme relied on a team from Quinn Emanuel Urquhart & Sullivan led by Munich-based partner Marcus Grosch, who advises the biotech company in the German proceedings together with Andreas Hahne. They cooperated with General Counsel Mark Snyder.
The law firm also represents Halozyme in the US proceedings. Initially the law firm also represented Halozyme in the UK proceedings, co-counselling with a team from Osborne Clarke, which in the meantime has taken over the lead. A team from Brinkhof represented Halozyme in the Dutch proceedings.
MSD instructed its long-standing advisors from Hogan Lovells Cadwalader. Düsseldorf-based partners Miriam Gundt and Andreas von Falck led the German proceedings, working with patent attorney Felipe Zilly. The team also included counsels Kerstin Jonen and double qualified Lars Fabian Blume and from the associates lawyer Lea Gröblinghoff, double qualified Tobias Timmerscheid and patent attorney Jonas Rose.
From the in-house department at MSD, Mark Stewart, Head of Global Intellectual Property Litigation attended the hearing, accommpanied by Chief IP Counsel James Horgan and Daniela Tröppner, Director Legal & Compliance.
Hogan Lovells Cadwalader also represents MSD in parallel proceedings across Europe.
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information